Dr. Jimmy Lin, MD, PhD, MHS, is a distinguished figure in the field of cancer genomics, renowned for his pioneering work in advancing cancer research and treatment. With a career spanning prestigious institutions like Johns Hopkins and the National Cancer Institute, as well as companies like Natera and Freenome, Dr. Lin has been instrumental in groundbreaking projects such as genome-wide sequencing of human cancers and the development of liquid biopsy cancer monitoring diagnostics. His research focuses on applying computational and genomics methods to understand cancer, translating scientific discoveries into clinical diagnostics and therapies. Dr. Lin's contributions have significantly advanced the field of cancer genomics, with a focus on identifying genetic alterations in various cancers and developing new approaches for cancer therapy. Additionally, as the Founder and President of the Rare Genomics Institute, he leverages technological advances in cancer research to combat rare diseases, showcasing his commitment to driving innovation and social impact in the genomics and healthcare sectors.
Areas of Expertise
AI and machine learning, Bioinformatics, Biotechnology, Cancer genomics, Computation biology, Early cancer detection, Impact investing, Rare diseases, Research
